News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Array BioPharma, Inc. (ARRY) Outlines Path to Market for New Myeloma Drug



10/31/2013 8:51:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

This morning, Array Biopharma will outline its plans to investors to get its first wholly-owned drug, a treatment for the blood cancer multiple myeloma, approved by the Food and Drug Administration. Codenamed ARRY-520, the medicine is a exciting because it is a new class of medicine, completely different from the immunomodulatory agents, including thalidomide, Revlimid, and Pomalyst, all made by Celgene CELG -1.83%, and the proteasome inhibitors Velcade, sold by Takeda, and Kyprolis, from Amgen AMGN -0.32%. “In patients that have failed everything we believe 520 can offer benefit,” says Ron Squarer, Array’s chief executive.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES